Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia/Ib/II study of ALK-N001 for injection in advanced solid tumors
CTR20252185Phase 2Suspended
- Sponsor
- Zhejiang Anglikang Pharmaceutical
- Start
- Jun 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QHL-1618 in Nonhematologic neoplasms, esophageal cancer, small cell lung cancer (SCLC), gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Zhejiang Anglikang Pharmaceutical. Started Jun 2025; status: suspended.
02
Drugs
QHL-1618
03
Conditions
Nonhematologic neoplasmsesophageal cancersmall cell lung cancer (SCLC)gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20252185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252185.